Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Explore this paper's citation graph
Summary
Nivolumab combined with ipilimumab had clinically meaningful intracranial efficacy, concordant with extracranial activity, in patients with melanoma who had untreated brain metastases.
- Type
- article
- Published
- 2018-08-22
- Cited by
- 1,119
- References
- 17
- Access
- Open access
- OpenAlex
- https://openalex.org/W2888298425
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:52066717
Keywords
Ipilimumab, Nivolumab, Medicine, Melanoma, Metastatic melanoma
References
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
- Prognostic factors for survival in melanoma patients with brain metastases
- Stereotactic radiosurgery for brain metastases.
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- Diagnosis and treatment of melanoma brain metastasis: a literature review.
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
- Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
- Dabrafenib plus trametinib in patients with BRAF V600–mutant melanoma brain metastases (COMBI-MB): a multi-cohort, open-label, phase 2 trial
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Cited by
- Primary intracranial malignant melanoma: proposed treatment protocol and overall survival in a single-institution series of 15 cases combined with 100 cases from the literature.
- Advances in the systemic treatment of melanoma brain metastases
- Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)
- Finding Better Ways to Prevent Postpartum Hemorrhage.
- Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease
- What’s new under the Sun for ICIs?
- Two Decades of the Impact of Tasmanian Devil Facial Tumor Disease.
- For Your Patients-Neuro-Oncology
- Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
- Kombinierte Immuntherapie für Patienten mit Hirnmetastasen eines malignen Melanoms: Deeskalation nur unter kontrollierten Bedingungen und engmaschiger Bildgebung
- Recent advances in managing brain metastasis
- Kombination aus Nivolumab und Ipilimumab auch bei Hirnmetastasen hoch effektiv!
- Preoperative Stereotactic Radiosurgery for Brain Metastases
- Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma
- Immuntherapie auch bei Hirnmetastasen des malignen Melanoms wirksam
- Immuntherapie wirkt auch gegen Melanommetastasen im Gehirn
- Improved Survival Outcomes for Kidney Cancer Patients with Brain Metastases
- Exploiting Autoimmunity Unleashed by an Off-Label Low-Dose Immune Checkpoint Blockade to Treat Advanced Cancer
- Re‐examining the role of adjuvant radiation therapy
- Checkpointhemmerkombination zeigt intrakranielle Aktivität beim Melanom
Related papers
- Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
- Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma
- Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
- TNFSF9 is associated with favor tumor immune microenvironment in patients with renal cell carcinoma who are treated with the combination therapy of nivolumab and ipilimumab
- The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
- LBA47 Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study
- Combined immunotherapy improves survival in metastatic melanoma
- Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma.